Anakinra
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Anakinra: Extracutaneous mastocytoma
One-Sentence Summary
Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that is marketed in Canada. The TxGNN model predicts it may be effective for extracutaneous mastocytoma, with a score of 0.9993. There are currently no clinical trials and no publications supporting this specific prediction, so it remains a model-only hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Extracutaneous mastocytoma |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for anakinra are not available in the data compiled for this report. Based on general knowledge, anakinra blocks IL-1 signalling, a pathway central to many inflammatory conditions.
A speculative link is that IL-1 signalling may contribute to inflammation driven by mast cells. However, nothing in the data compiled for this report supports this link. No trials or publications address extracutaneous mastocytoma, and the similarity to the drug’s established uses has not been assessed. The prediction should therefore be treated as a hypothesis for further investigation, not as a finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02245913 | KINERET | Not specified | Not specified |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 recorded interactions. The listed examples include:
- Major: deferiprone.
- Moderate: corticosteroids (hydrocortisone, betamethasone, budesonide, dexamethasone, prednisolone, prednisone, triamcinolone), simvastatin, apixaban, rivaroxaban, dicoumarol, and radiopharmaceutical or radiolabelled antibody agents (ibritumomab tiuxetan, iobenguane I-131, tositumomab).
- Minor: zinc salts (acetate, gluconate, sulfate).
Please also refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9993), but no clinical trial or publication studies anakinra in extracutaneous mastocytoma. This places the evidence at L5, model prediction only, which is not enough to justify moving forward.
To proceed, the following is needed:
- Preclinical or mechanistic data showing a role for IL-1 signalling in this disease
- Published case reports or early-phase studies of IL-1 blockade in mast cell neoplasms
- Mechanism-of-action data for anakinra
- Review of the Health Canada package insert for warnings and contraindications
- A safety plan that takes the interaction findings into account, particularly the major interaction with deferiprone
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.